These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26627724)

  • 41. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
    Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
    Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chromogranin A: is it a useful marker of neuroendocrine tumors?
    Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
    J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.
    Kidd M; Drozdov I; Modlin I
    Endocr Relat Cancer; 2015 Aug; 22(4):561-75. PubMed ID: 26037279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chromogranin A and neuroendocrine tumors].
    Díaz Pérez JÁ; Currás Freixes M
    Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromogranin A in gastrinomas: Promises and pitfalls.
    Rehfeld JF
    Clin Chim Acta; 2015 Jun; 446():15-20. PubMed ID: 25861845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.
    Jensen KH; Hilsted L; Jensen C; Mynster T; Rehfeld JF; Knigge U
    Scand J Gastroenterol; 2013 Jan; 48(1):70-7. PubMed ID: 23094948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors.
    Kim M; Lee S; Lee J; Park SH; Park JO; Park YS; Kang WK; Kim ST
    Cancer Res Treat; 2016 Jan; 48(1):153-61. PubMed ID: 25779359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
    Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
    Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
    Chou WC; Hung YS; Hsu JT; Chen JS; Lu CH; Hwang TL; Rau KM; Yeh KY; Chen TC; Sun CF
    Neuroendocrinology; 2012; 95(4):344-50. PubMed ID: 22343505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
    Rustagi S; Warner RR; Divino CM
    J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
    Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
    Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
    Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
    Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
    Dittadi R; Gion M
    Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
    [No Abstract]   [Full Text] [Related]  

  • 56. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
    Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
    Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
    Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.